In the last eighteen months we have treated 15 patients with established or suspected fungal infections with intravenous miconazole. The distribution of age and sex of these patients can be seen in Table 1 . The patients were mainly males and most of them were older than 50 years. The duration of treatment varied from one to thirty-four days. A very short course of treatment was usually given in patients where a diagnosis of fungal infection was not proven by positive cultures. Total doses varied from 0.4 to 28 g, with an average of 9.8 g. Daily doses varied from 0.4 to 1.2 g. Usually the patients received 800 mg daily in two separate intravenous infusions. (Table 3 ). All these patients had several positive cultures before the treatment. A certain increase has occurred in the incidence of aspergillus infections in recent years. In addition we had a residual group of patients where a fungal infection could not be proven by cultures (Table 4 ). In these patients the tolerance but not the clinical efficacy of the drug could be evaluated.
The clinical effects of the drug are summarized in Table 5 . Clinical and mycological success was achieved in 4 patients and some improvement in these parameters was seen in a further 3. But such a summary does not give very much information about the efficacy of miconazole, if only because there are several cases which are not evaluable. A fuller picture can be drawn by considering the detailed course of 4 typical cases of aspergillus infection. Case 1 W J, 61-year-old man. Had been hypertensive since 1967. Since November 1974 he suffered from stenocardia and increasing dyspnoea. He was admitted to hospital with fever of 40°C, signs of pneumonia and cardiac insufficiency.
The chest X-ray showed infiltration in both sides, which became more marked after 5 days. The electrocardiogram revealed some signs of an old coronory infarction.
Under treatment with antibiotics the fever decreased slowly. During antibiotic therapy there were six cultures of sputum positive for Aspergillus fumigatus. We started therapy with 800 mg of intravenous miconazole daily, which was well tolerated. Cultures during and after the treatment were negative for aspergillus. The pulmonary infiltrations became smaller and disappeared slowly. The patient was dismissed in PLATE II (see text, p 49) a good condition one week after termination of the therapy. Several follow-up examinations showed no evidence of aspergillus infection. We regard the treatment as a clinical and microbiological success, even though differentiation of the chemotherapeutic effect from the spontaneous course of the infection is difficult.
Case 2 H E, 68-year-old diabetic woman. She underwent vulvectomy, due to kraurosis vulvv. Some days later she had fever and an increase in transaminase levels. Ten days after the operation she was admitted to hospital.
The liver disease was regarded as halothane hepatitis. Radiographic examination revealed peribronchial infiltrations. Five sputum cultures yielded Aspergillus fumigatus, often in great numbers but no other facultative pathogenic organisms.
We regarded the lung disease as postoperative infection with aspergillus and started therapy with miconazole. During and after therapy, the sputum became negative for aspergillus. Her clinical status improved and the leukocytosis disappeared. The treatment was discontinued after 19 days and the patient was dismissed 10 days later in good health.
We classified this treatment as a clinical and microbiological success, but there remain some doubts about the real etiological role of aspergillus in this case.
Case 3 V A, 47-year-old male employee. He underwent pneumectomy of the right lung in 1958 because of pulmonary tuberculosis. During recent years he had several attacks of bronchitis. Four out of 8 sputum cultures were positive for Aspergillus fumigatus. The sputum was sometimes slightly bloody and the patient had a cough. No pulmonary infiltrations could be observed in chest X-rays. We considered the disease to be an infection of the right residual bronchus with Aspergillusfumigatus.
We treated the patient for 15 days with 800 mg of miconazole daily. He tolerated the therapy well except for a slight phlebitis of the veins used for the infusions. An attempted application of miconazole in 1/10 dilution by aerosol was unsuccessful, since the patient did not tolerate the taste.
In cultures during and after the treatment no further growth of aspergillus could be detected. Follow-up studies were performed over a long period. Only once, after 7 months, did one positive culture reappear, but subsequent repeated cultures remained negative.
We regarded this condition as being an aspergillus infection of the residual bronchus, but there are some doubts about this conclusion.
Case 4 D R, 72-year-old man. He suffered from alcoholism and an inactive pulmonary tuberculosis of the right upper lobe. From mid 1974 to early 1975 he was hospitalized in a sanatorium for the treatment of tuberculosis and then discharged under treatment with isonictonic acid hydrazide and ethambutol.
In March 1975 he was admitted to hospital in a poor general condition and with an acute febrile illness. The chest X-ray gave evidence of an infiltration of the right middle lobe but no residual cavities were seen. Under treatment with cephazolin there was an increase of the pulmonary infiltrations. Aspergillus fumigatus was isolated from several cultures of the sputum. We started treatment by administering 800-120 mg of miconazole daily. Sputum cultures continued to be positive. We stopped the treatment after 34 days. The patient died one week later.
Autopsy revealed a chronic pneumonia due to aspergillus together with an inactive tuberculosis. As the clinical and microbiological effect of the therapy was poor,we regard the case as a failure.
Observed side-effects of treatment have included one patient with local phlebitis after miconazole infusion and another patient who, after 5 days treatment with miconazole, developed dyspncea and a brief skin erythema during the infusion. This sideeffect looked like an allergic phenomenon. The reaction was quite severe, resembling a bacteriolysis or Herxheimer reaction, so that the doctor on the ward gave him 25 mg prednisone, which helped the patient immediately. The poor condition of this leukaemic patient did not allow for further administration or for allergy tests to miconazole.
This patient suffered from a lung infection by aspergillus with large cavities. After the treatment, all further cultures and also the autopsy 6 weeks later were negative for aspergillus.
In conclusion it seems that both systemic aspergillus and candida infections may be treated with miconazole. Good tolerance to the drug will probably justify the clinical use not only in patients with culturally positive mycoses, but also in those patients at a high risk of secondary mycotic infections, such as those suffering from leuktmia.
Summary
The present study reports on 15 patients with confirmed or suspected secondary fungal infection, who were treated with intravenous miconazole and a daily dose of 0.4 to 28 g (mean 9.8 g). The mycological findings confirmed infection with Aspergillusfumigatus in 6 patients and severe infection with Candida albicans in 4. Clinically mycological cures were achieved in 4 patients and some improvement was found in 3 others.
The excellent patient tolerance of the drug makes it seem a likely treatment not only for patients with mycologically confirmed infection but also for those whose condition exposes them to a high risk of fungal infection.
DISCUSSION
Dr R Negroni (Buenos Aires) asked what were Professor Stille's parameters for the diagnosis of aspergillosis of the lung. The cultivation of the fungi in the sputum was not enough because it may be a contaminant. Secondly, he had experience of intercavital invasion by Aspergillus fumigatus and in this type of aspergillosis of the lung, miconazole was not successful.
Professor Stille knew the difficulties in diagnosing aspergillosis and said that sometimes there were patients where aspergillus found in the sputum was of no clinical importance. In all their cases they had found aspergillus repeatedly and in large numbers, together with a typical clinical situation. Nevertheless he had some doubts. Perhaps some of their patients first had lung emboli, with aspergillus as a secondary superinfection. But in general it was rare to find aspergillus repeatedly in the sputum of a healthy patient. Where it was found, even where the patient was only a carrier, if he could be made negative this was also a sign of positive chemotherapy.
Professor Stille also said he had not treated a case of aspergilloma. In his opinion, aspergilloma was an infection outside the body and could not be treated as a systemic infection. Chemotherapy required the technique of intercavitary instillation.
